Oulu-based Ginolis Ltd. and CELLINK AB from Sweden have entered into an agreement where CELLINK acquires 100 per cent of Ginolis shares.
With this acquisition, Ginolis will be a part of CELLINK Industrial Solutions along with Scienion and Cellenion.The acquisition’s completion is expected to occur by 1st of March 2021 Ginolis will remain under the current entity and management post-transaction.
Ginolis strengthens its market position
CELLINK’s vast global network of locations and distributors strengthen Ginolis’s current market position and offer new potential in countries where the company do not yet have a presence. In addition, Ginolis will benefit from CELLINK’s extensive resources and expertise in their future product development projects, enabling even better to serve their customers.
“Over the last 11 years, we have developed a strong foundation and built well-renowned customer relationships within our industry. As a current partner to CELLINK, we are well acquainted with the culture, the technology, and innovation-driven agenda as well as their high ambitions. We look forward to becoming part of CELLINK’s bio convergence vision and bringing our expertise, products and workflow to a wider audience,” says Teijo Fabritius, CEO, Ginolis.
Synergy benefit for CELLINK’s operations
With the acquisition, CELLINK will gain synergies in the field of microfluidics, diagnostics, and bioprinting; further strengthening its bio convergence powerhouse position. Ginolis’ innovative modular robotics and workflows, the Xanthia platform, enable precision-oriented manufacturing of microfluidic, multiplex assays, medical devices, and lateral flow IVD tests known as PoC tests. The Group will also gain the capacity to deliver large-scale automation projects for the medical and diagnostic industries.
“We are very excited to welcome Ginolis onboard to the CELLINK Family. The cutting-edge modularity of the Ginolis robotics make the platforms ideal for scale-up of bioprinting systems and product offerings, enabling strategic and industrial expansion of our bioprinting capabilities to pharma and biotech customers; a mission the Group committed to two years ago. Many of the great tools offered by Ginolis, developed by the great people in the company, will ensure higher quality bioprinting experiments and results, faster throughput of printed tissues, and more reliable and reproducible data. For instance, Ginolis’ 3D Metrology system, the Pixie, will be a perfect plugin to our bioprinting workflows that will enable rapid quality assurance of bio-printed tissues to ensure a whole new level of reproducibility. CELLINK will also gain the capacity to deliver large-scale automation to customers in the medical technology field and diagnostics, as well as an associated portfolio of innovative consumables that complement our existing offering,” Erik Gatenholm, CEO, CELLINK, summarises.
Founded in 2016, CELLINK is the leading bio convergence company that provides technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, multi-omics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical and cosmetic industries. CELLINK’s products are trusted by more than 1,800 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 1,300 publications. CELLINK is creating the future of medicine. Visit cellink.com to learn more. CELLINK is listed on the Nasdaq Stockholm under CLNK B.
For more information on CELLINK, please visit www.cellink.com
In case of questions, please contact email@example.com.